

# Synthesis, Characterization and Biological Evaluation of Some Novel N-Mannich Bases of Benzimidazole Derivative.

Pragya Kawde<sup>1</sup>, Govind Nayak<sup>2</sup>, Parul Mehta<sup>3</sup>, Shivakant Shukla<sup>4</sup>

<sup>1</sup>Student Mpharma, Lakshmi Narain College of Pharmacy, Bhopal, India<sup>2</sup>Professor, Lakshmi Narain College of Pharmacy, Bhopal, India

<sup>3</sup>Principal, Lakshmi Narain College of Pharmacy, Bhopal, India

<sup>4</sup>Professor, Lakshmi Narain College of Pharmacy, Bhopal, India

## ABSTRACT

Over the past few decades, Mannich bases of heterocyclic molecules have been grabbing the attention of the synthetic chemists for their wide gamut of biological activities ranging from antibacterial, anticancer, antiparkinson to anticonvulsant, anti-inflammatory, analgesic and anti-HIV. Using the knowledge of important features a novel series was designed to obtain improved antibacterial and antifungal activity. Therefore in the present research, we decided to synthesize 2-substituted benzimidazole derivatives by conventional method. Further the study will extended to introduce sulphanilamide and piperazine group substitution on N-1 position of 2-substituted benzimidazole by Mannich reaction and to screen the newly synthesized compounds for their antibacterial and antifungal activity.

## INTRODUCTION :

Mannich Bases of wide variety of heterocyclic/nonheterocyclic nucleus have been revealed to possess cytotoxic, antibacterial, antifungal, anticonvulsant, anti-inflammatory and antimalarial activity. Benzimidazole derivatives were reported to possess antibacterial, antifungal, anti-inflammatory, antiviral, antitubercular, antioxidant, antiprotozoal, anthelmintic, antihypertensive, antidiabetic and antiulcer activity. The presence of basic mannich side chain in a drug may overcome the water insolubility problem through the formation of hydrochlorides.

The various strategies are available for the synthesis of benzimidazole and using a variety of starting material. In literature review, there are two general methods for the synthesis of 2-substituted benzimidazoles revealed that the condensation of Ophenylenediamine with carboxylic acid derivatives like anhydrides, ester, amides and acid chlorides to yield the corresponding the titled benzimidazole compound which often requires strong acidic conditions, and sometimes combines with very high temperatures or microwave irradiation. The other way involves a two-step procedure that includes the oxidative cyclo-dehydrogenation of schiff bases, which are often generated from the condensation of phenylenediamines and aldehydes.


In the present research, we decided to synthesize 2-substituted benzimidazole derivatives by conventional method. Further the study will extended to introduce sulphanilamide and piperazine group substitution on N-1 position of 2-substituted benzimidazole by Mannich reaction and to screen the newly synthesized compounds for their antibacterial and antifungal activity. Identification and characterization of synthesized compound was done by FT IR, <sup>1</sup>H NMR, UV spectroscopy and Mass spectra method.

**MATERIALS AND METHODS :**
**1. Experimental Section-**


The melting points were recorded in open capillaries on Elico melting point apparatus and were uncorrected. Spectral analysis were performed in the Sophisticated Analytical Instrumentation, using <sup>1</sup>H NMR (Bruker – NMR 500MHz) Spectrometer, Mass (JEOL GC mate) spectrometer, and IR (Thermo Fischer – Nicolet iS5) and UV- Visible Spectrometer (Double beam UV Spectrometer – SHIMADZU -1700). Analytical samples were dried in vacuum and they were free of significant impurities on TLC. For antimicrobial activity by using two gram positive bacteria (*Staphylococcus aureus* MTCC 740 and *Bacillus subtilis* MTCC 121) and two gram negative bacteria (*Escherichia coli* MTCC 1302 and *Pseudomonas aeruginosa* MTCC 741) and two fungal organisms (*Candida albicans* ATCC 24433 and *Trichophyton rubrum* ATCC 2327).

**• Procedure for synthesis of compounds SR<sub>1</sub>, SR<sub>2</sub> and SR<sub>3</sub> :**


13.5 g (0.125 mol) of O-phenylene diamine was placed in a 250 ml of round bottom flask and added 10.2 g (0.17 mol) of acetic acid for **SR<sub>1</sub>**, 14.96 g (0.17 mol) of propionic acid for **SR<sub>2</sub>** and 17.34 g (0.17 mol) of butyric acid for **SR<sub>3</sub>**. The mixture was heated on a water bath at 100° C for 6-8 h, cooled and added 10% sodium hydroxide solution slowly with constant rotation of the flask, until the mixture was just alkaline to litmus. The crude benzimidazole derivative was filtered at the pump, and then washed with ice cold water, drained well and washed again with 25 ml of cold water. The crude product was dissolved in 200 ml of boiling water; 2 g of decolorizing carbon was added and digested for 15 min. The product was filtered rapidly at the pump through preheated buchner funnel and flask. The filtrate was cooled to about 10° C and the filtered product was again washed with 25 ml of cold water, dried at 100° C and weighed.



**(a) Synthesis of 2-methyl-benzimidazole (SR<sub>1</sub>)**




**(b) Synthesis of 2-ethyl-benzimidazole (SR<sub>2</sub>)**




### Synthesis of 2-propyl-benzimidazole (SR<sub>3</sub>)

• **Procedure for synthesis of compounds SR<sub>4</sub>, SR<sub>5</sub> and SR<sub>6</sub> :**


To the 15 ml of methanolic solution, 0.66 g (0.005 mol) of 2-methyl benzimidazole for **SR<sub>4</sub>**, 0.73 g (0.005 mol) of 2-ethyl benzimidazole for **SR<sub>5</sub>** and 0.80 g (0.005 mol) of 2-propyl benzimidazole for **SR<sub>6</sub>** was added to 0.86 g (0.005 mol) of sulphanilamide slowly with constant stirring under rigorous ice cooling. The reaction mixture was cooled well and 0.138 ml (0.005 mol) of formaldehyde solution (37% v/v) was added slowly with constant stirring. The reaction mixture was then adjusted to the pH of 3.5 with hydrochloric acid. The reaction mixture was kept in efficient ice cooling for half an hour to avoid losses of formaldehyde and then refluxed on water bath up to 3 h. The reflux time was dependent upon the sulphonamide chosen. After refluxing, the refluxed mixture was cooled at 0° C for 4 days, when crystallized product was obtained, which was recrystallized with dry distilled ethanol and DMF.



### (d) Synthesis of 1-((sulphanilamido) methyl)-2-methyl-benzimidazole SR<sub>4</sub>






(e) Synthesis of 1-((sulphanilamido) methyl)-2-ethyl-benzimidazole SR<sub>5</sub>



(f) Synthesis of 1-((sulphanilamido) methyl)-2-propyl-benzimidazole SR<sub>6</sub>




• Procedure for synthesis of compounds SR<sub>7</sub>, SR<sub>8</sub> and SR<sub>9</sub> :

To a solution 1.32 g (0.01 mol) of 2-methyl benzimidazole for SR<sub>7</sub>, 1.46 g (0.01 mol) of 2-ethyl benzimidazole for SR<sub>8</sub> and 1.60 g (0.01 mol) of 2-propyl benzimidazole for SR<sub>9</sub> in 15 ml of ethanol, 0.86 g (0.01 mol) of piperazine and 0.30 ml (0.01 mol) of formaldehyde solution (37% v/v) were added slowly with constant stirring under rigorous ice cold condition. The reaction mixture was kept in efficient ice cooling for half an hour to avoid losses of formaldehyde and then the reaction mixture was refluxed on water bath up to 30 min. The refluxed mixture was cooled at 0° C for 2-3 days in deep freeze. When crystallized product was obtained, filtered and dried. The product obtained was purified by recrystallized with dry distilled ethanol.




N-Mannich base of 2-methyl benzimidazole

**(g) Synthesis of 1-((piperazino) methyl)-2-methyl-benzimidazole (SR7)**



N-Mannich base of 2-ethyl benzimidazole

**(h) Synthesis of 1-((piperazino) methyl)-2-ethyl-benzimidazole (SR8)**



**(i) Synthesis of 1-((piperazino) methyl)-2-propyl-benzimidazole (SR<sub>9</sub>)**

**Table - 1: Physical and Analytical data of the synthesized compounds**

Code No.	Name	Nature	Solubility	Molecular weight (g)	Molecular formula	Melting point (° C)	percentage yield (% w/w)	R <sub>f</sub> values (CH <sub>3</sub> OH:H <sub>2</sub> O) 8:2
SR <sub>1</sub>	2-methyl-1-H-benzimidazole	Light yellow crystalline, solid	Freely soluble: Methanol. Soluble: Ethanol, benzene, acetone and chloroform. Insoluble: Water, hexane and ethyl acetate.	132.16	C <sub>8</sub> H <sub>8</sub> N <sub>2</sub>	176 * (174-178)	60.73	0.92
SR <sub>2</sub>	2-ethyl-1-H-Benzimidazole	Yellowish white crystals	Freely soluble: Methanol and acetone. Soluble: Benzene, ethanol, ethyl acetate and chloroform.	146.18	C <sub>9</sub> H <sub>10</sub> N <sub>2</sub>	211 * (213-215)	38.89	0.72

			Insoluble: Hexane and water.					
SR <sub>3</sub>	2-propyl-1-H-benzimidazole	ght yellow crystals	Freely soluble: Methanol. Soluble: Benzene, ethanol, ethyl acetate, chloroform and acetone. Insoluble: Hexane and water.	160.21	C <sub>10</sub> H <sub>12</sub> N <sub>2</sub>	183 * (180-184)	85.86	0.78
SR <sub>4</sub>	1-((sulphanilamido) methyl)-2-methyl-benzimidazole	ackish red crystals	Soluble: Methanol. Slightly soluble: Acetone, benzene, ethanol, ethyl acetate and chloroform. Insoluble: Hexane and water.	316.37	C <sub>15</sub> H <sub>16</sub> N <sub>4</sub> O <sub>2</sub> S		142	45.58 0.93
SR <sub>5</sub>	1-((sulphanilamido) methyl)-2-ethyl-benzimidazole	Light yellowish white powder	Soluble: Acetone. Slightly soluble: Methanol, ethyl acetate and chloroform. Insoluble: Ethanol, benzene, hexane and water.	330.40	C <sub>16</sub> H <sub>18</sub> N <sub>4</sub> O <sub>2</sub> S		123	31.61 0.81
SR <sub>6</sub>	1-((sulphanilamido) methyl)-2-propyl-benzimidazole	Black crystals	Soluble: Methanol, ethanol and acetone. Slightly soluble: Benzene, ethyl acetate and chloroform. Insoluble: Hexane and water.	344.43	C <sub>17</sub> H <sub>20</sub> N <sub>4</sub> O <sub>2</sub> S		149	28.45 0.82

SR <sub>7</sub>	1-((piperazino methyl)-2-methyl-benzimidazole	ght brown crystals	Soluble: Methanol. Slightly soluble: Ethanol, hexane, acetone, ethyl acetate and chloroform. Insoluble: Benzene and water.	230.30	C <sub>13</sub> H <sub>18</sub> N <sub>4</sub>	148	71.17	0.86
SR <sub>8</sub>	1-((piperazino methyl)-2-ethyl-benzimidazole	rownish crystals	Soluble: Methanol and ethanol. Slightly soluble: Chloroform, ethyl acetate, acetone and hexane. Insoluble: Benzene and water.	244.33	C <sub>14</sub> H <sub>20</sub> N <sub>4</sub>	161	92.70	0.84
SR <sub>9</sub>	1-((piperazino methyl)-2-propyl-benzimidazole	rownish crystals	Soluble: Methanol, ethanol and chloroform. Slightly soluble: Acetone, ethyl acetate and benzene. Insoluble: Hexane and water.	258.36	C <sub>15</sub> H <sub>22</sub> N <sub>4</sub>	174	69.10	0.87

➤ **Spectral Data of synthesized Compounds:**

**(a) 2-methyl-benzimidazole (SR<sub>1</sub>):**

IR (KBr cm<sup>-1</sup>): 3385 (s) N-H stretching, 3057 (w) Aromatic (=C-H) stretching, 2916 (m) Aliphatic C-H stretching in CH<sub>2</sub>, 1624 (s) C=C stretching, 1591 (s) C=N stretching, 736 (s) Aromatic C-H out-of-plane bending.

UV:  $\lambda_{\max}$  - 280.5 ( $\epsilon_{\max}$  0.2668)

$\lambda_{\max}$  - 243.0 ( $\epsilon_{\max}$  1.0140)

<sup>1</sup>H NMR: 7.70  $\delta$  (2H, m, Ar-H of C<sub>4</sub> and C<sub>7</sub>), 7.26  $\delta$  (2H, m, Ar-H of C<sub>5</sub> and C<sub>6</sub>), 5.0  $\delta$  (1H, s, broad, NH), 2.42  $\delta$  (3H, s, -CH<sub>3</sub>).

**(b) 2-ethyl-benzimidazole (SR<sub>2</sub>):**

IR (KBr cm<sup>-1</sup>): 316(s) N-H stretching, 3052 (w) Aromatic (=C-H) stretching, 2973(m) Aliphatic C-H stretching in -CH<sub>2</sub>, 1622 (s) C=C stretching, 1589 (s) C=N stretching, 1324 (s) CH<sub>3</sub> bending, 1457 (m) CH<sub>2</sub> bending, 794 (s) Aromatic C-H out-of-plane bending.

UV:  $\lambda_{\max}$  - 243.0 ( $\epsilon_{\max}$  0.4058)



$\lambda_{\max}$  - 274.0 ( $\epsilon_{\max}$  0.4591)

<sup>1</sup>H NMR: 7.70  $\delta$  (2H, m, Ar-H of C<sub>4</sub> and C<sub>7</sub>), 7.26  $\delta$  (2H, m, Ar-H of C<sub>5</sub> and C<sub>6</sub>), 5.0  $\delta$  (1H, s, broad, NH), 2.59  $\delta$  (2H, q, CH<sub>2</sub>, broad), 1.24  $\delta$  (3H, t, -CH<sub>3</sub>).

**(c) 2-propyl-benzimidazole (SR<sub>3</sub>):**

IR (KBr cm<sup>-1</sup>): 3385 (s) N-H stretching, 3055 (w) Aromatic (=C-H) stretching, 2957 (m) Aliphatic C-H stretching in -CH<sub>2</sub>, 1632 (s) C=C stretching, 1591 (s) C=N stretching, 1320 (s) CH<sub>3</sub> bending, 1457 (w) CH<sub>2</sub> bending, 748 (s) Aromatic C-H bending.

UV:  $\lambda_{\max}$  - 239.0 ( $\epsilon_{\max}$  0.5980)

$\lambda_{\max}$  - 296.5 ( $\epsilon_{\max}$  0.2899)

<sup>1</sup>H NMR: 7.70  $\delta$  (2H, m, Ar-H of C<sub>4</sub> and C<sub>7</sub>), 7.26  $\delta$  (2H, m, Ar-H of C<sub>5</sub> and C<sub>6</sub>), 5.0  $\delta$  (1H, s, broad, NH), 2.55  $\delta$  (2H, t, -CH<sub>2</sub>), 1.66  $\delta$  (2H, q, -CH<sub>2</sub>), 0.96  $\delta$  (3H, t, -CH<sub>3</sub>).

**(d) 1-((sulphonamido)-methyl)-2-methyl benzimidazole (SR<sub>4</sub>):**

IR (KBr cm<sup>-1</sup>): 3376 (s) 1° N-H stretching in sulphonamide, 3263 (s) 2° N-H stretching in sulphonamide, 3063 (w) Aromatic (=C-H) stretching, 2921 (m) C-H stretching in -CH<sub>2</sub>, 1595 (s) C=N stretching, 1460 (s) C=C stretching, 1438 (m) CH<sub>3</sub> asymmetric bending, 1312 (s) SO<sub>2</sub> stretching, 1386 (s) C-N stretching (Aromatic tertiary amine), 746 (s) C-H out-of-planes bending (Aromatic C-H).

UV:  $\lambda_{\max}$  - 262.5 nm ( $\epsilon_{\max}$  - 1.4568)

<sup>1</sup>H NMR: 7.10 – 7.64  $\delta$  (8H, m, Ar-H – C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub> and 4-phenyl protons), 6.06  $\delta$  (2H, s, -CH<sub>2</sub>), 4.57  $\delta$  (2H, s, -SO<sub>2</sub>NH<sub>2</sub>), 5.82  $\delta$  (1H, s, -NH), 2.53  $\delta$  (3H, s, -CH<sub>3</sub>).

**(e) 1-((sulphonamido)-methyl)-2-ethyl benzimidazole (SR<sub>5</sub>):**

IR (KBr cm<sup>-1</sup>): 3378 (s) 1° N-H stretching in sulphonamide, 3263 (s) 2° N-H stretching in sulphonamide, 3057 (w) Aromatic (=C-H) stretching, 2938 (m) C-H stretching in -CH<sub>2</sub>, 1597 (s) C=N stretching, 1460 (s) C=C stretching, 1438 (m) Aliphatic CH<sub>2</sub> bending, 1313 (s) SO<sub>2</sub> stretching, 1387 (s) C-N stretching (Aromatic tertiary amine), 744 (s) C-H out-of-planes bending (Aromatic C-H)

UV:  $\lambda_{\max}$  - 240.0 nm ( $\epsilon_{\max}$  - 0.7504)

$\lambda_{\max}$  - 293.0 nm ( $\epsilon_{\max}$  - 0.3855)

<sup>1</sup>H NMR: 7.12 – 7.64  $\delta$  (8H, m, Ar-H – C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub> and 4-phenyl protons), 6.14  $\delta$  (2H, s, -CH<sub>2</sub>), 5.83  $\delta$  (1H, s, -NH), 4.57  $\delta$  (2H, s, -SO<sub>2</sub>NH<sub>2</sub>), 2.80 (2H, q, -CH<sub>2</sub>), 1.28  $\delta$  (3H, t, -CH<sub>3</sub>).

**(f) 1-((sulphonamido)-methyl)-2-propyl benzimidazole (SR<sub>6</sub>):**

IR (KBr cm<sup>-1</sup>): 3385 (s) 1° N-H stretching in sulphonamide, 3289 (s) 2° N-H stretching in sulphonamide, 3026 (w) Aromatic (=C-H) stretching, 2931 (m) C-H stretching in -CH<sub>2</sub>, 1561 (s) C=N stretching, 1458 (s) C=C stretching, 1421 (m) Aliphatic CH<sub>2</sub> bending, 1320 (s) SO<sub>2</sub> stretching, 1383 (s), C-N stretching (Aromatic tertiary amine), 748 (s) C-H out-of-planes bending (Aromatic C-H).

UV:  $\lambda_{\max}$  - 263.0 nm ( $\epsilon_{\max}$  - 0.7203)

<sup>1</sup>H NMR: 7.10 – 7.64  $\delta$  (8H, m, Ar-H – C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub> and 4-phenyl protons), 6.18  $\delta$  (2H, s, -CH<sub>2</sub>), 5.76  $\delta$  (1H, s, -NH), 4.60  $\delta$  (2H, s, -SO<sub>2</sub>NH<sub>2</sub>), 2.95  $\delta$  (2H, t, -CH<sub>2</sub>), 1.78 – 1.85  $\delta$  (2H, m, -CH<sub>2</sub>), 0.95  $\delta$  (3H, t, -CH<sub>3</sub>).

**(g) 1-((piperazino)-methyl)-2-methyl benzimidazole (SR<sub>7</sub>):**

IR (KBr cm<sup>-1</sup>): 3409 (w) 2° N-H stretching in piperazine, 3063 (w) Aromatic (=C-H) stretching, 2933 (m) C-H stretching in CH<sub>2</sub> group, 2874 (m) C-H stretching in piperazine, 1622 (s) C=N stretching, 1450 (s) C=C stretching, 1415 (s) CH<sub>2</sub> asymmetric bending, 1346 (s) C-N stretching (Aromatic tertiary amine), 736 (s) C-H out-of-plane bending (Aromatic C-H).

UV:  $\lambda_{\max}$  -280.0 nm ( $\epsilon_{\max}$  - 0.3619)

$\lambda_{\max}$  -273.5 nm ( $\epsilon_{\max}$  - 0.2915)

$\lambda_{\max}$  -237.5 nm ( $\epsilon_{\max}$  - 0.3762)

<sup>1</sup>H NMR: 7.15 – 7.64  $\delta$  (4H, m, Ar-H – C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub> and C<sub>7</sub>), 5.47  $\delta$  (2H, s, -CH<sub>2</sub>), 2.53  $\delta$  (3H, s, -CH<sub>3</sub>), 2.37 – 2.93  $\delta$  (8H, m, CH<sub>2</sub> of piperazine), 1.13  $\delta$  (1H, s, -NH).

**(h) 1-((piperazino)-methyl)-2-ethyl benzimidazole (SR<sub>8</sub>):**

IR (KBr cm<sup>-1</sup>): 3416 (w) 2° N-H stretching in piperazine, 3053 (w) Aromatic (=C-H) stretching, 2936 (m) C-H stretching in CH<sub>2</sub> group, 2796 (m) C-H stretching in piperazine, 1622 (s) C=N stretching, 1429 (s) CH<sub>2</sub> asymmetric bending, 1347 (s) C-N stretching (Aromatic tertiary amine), 741 (s) C-H out-of-plane bending (Aromatic C-H).

UV:  $\lambda_{\max}$  -280.5 nm ( $\epsilon_{\max}$  - 0.2572)

$\lambda_{\max}$  -274.5 nm ( $\epsilon_{\max}$  - 0.2415)

<sup>1</sup>H NMR: 7.15 – 7.64  $\delta$  (4H, m, Ar-H – C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>), 5.61  $\delta$  (2H, s, -CH<sub>2</sub>), 2.37 - 2.93  $\delta$  (10H, m, CH<sub>2</sub> of piperazine and CH<sub>2</sub> of ethyl group), 1.28  $\delta$  (3H, t, -CH<sub>3</sub>), 1.13  $\delta$  (1H, s, -NH).

**(i) 1-((piperazino)-propyl)-2-ethyl benzimidazole (SR<sub>9</sub>):**

IR (KBr cm<sup>-1</sup>): 3385 (w) 2° N-H stretching in piperazine, 3026 (w) Aromatic (=C-H) stretching, 2934 (m) C-H stretching in CH<sub>2</sub> group, 2874 (m) C-H stretching in piperazine, 1631 (s) C=N stretching, 1430 (m) CH<sub>2</sub> asymmetric bending, 1347 (s) C-N stretching (Aromatic tertiary amine), 749 (s) C-H out-of-plane bending (Aromatic C-H).

UV:  $\lambda_{\max}$  -280.5 nm ( $\epsilon_{\max}$  - 0.2052)

$\lambda_{\max}$  -274.0 nm ( $\epsilon_{\max}$  - 0.1995)

<sup>1</sup>H NMR: 7.15 – 7.64  $\delta$  (4H, m, Ar-H – C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub> and C<sub>7</sub>), 5.47  $\delta$  (2H, s, -CH<sub>2</sub>), 2.64 – 2.93  $\delta$  (8H, m, CH<sub>2</sub> of piperazine), 2.36  $\delta$  (2H, t, -CH<sub>2</sub>), 1.81 – 1.84  $\delta$  (2H, m, -CH<sub>2</sub>), 1.15  $\delta$  (1H, s, -NH), 0.94  $\delta$  (3H, t, -CH<sub>3</sub>).

**2. Biological Screening :****a) Evaluation of *in vitro* antibacterial activity:**

The *in vitro* anti bacterial study was carried out by using selected gastrointestinal tract infection (GIT) causing pathogens which includes two gram positive bacteria (*Staphylococcus aureus* MTCC 740 and *Bacillus subtilis* MTCC 121) and two gram negative bacteria (*Escherichia coli* MTCC 1302 and *Pseudomonas aeruginosa* MTCC 741). The synthesized compounds (SR<sub>4</sub> – SR<sub>9</sub>) were tested for anti bacterial activity by disc diffusion method (Collin C.H., *et al.*, 1995). They were dissolved in DMSO and sterilized by filtering through 0.45  $\mu$ m millipore filter. Final inoculum of 100  $\mu$ l suspension containing 10<sup>8</sup> CFU/ ml of each bacterium was used. Nutrient agar medium was prepared and sterilized by an autoclave (121° C and 15 lbs for 20 min) and it transferred to previously sterilized petridishes (9 cm in diameter). After solidification, petriplates was inoculated with gram negative bacterial organisms

*Escherichia coli* MTCC 1302, *Pseudomonas aeruginosa* MTCC 741 and gram positive bacterial organisms *Staphylococcus aureus* MTCC 740 and *Bacillus subtilis* MTCC 121 in sterile nutrient agar medium at 45° C under aseptic condition. Sterile Whatmann filter paper discs (previously sterilized in U.V. lamp) were impregnated with synthesized compounds at concentrations of 25, 100 µg/ disc were placed in the organism-impregnated petri plates under sterile condition. The plates were left for 30 min to allow the diffusion of compounds at room temperature. Antibiotic disc of ciprofloxacin (100 µg/ disc) was used as positive control, while DMSO used as negative control. Then the plates were incubated for 24 h at 37 ± 1° C. The zone of inhibition **Table 2** was calculated by measuring the minimum dimension of the zone of no microbial growth around each disc.

**Table 2: In vitro antibacterial activity of synthesized compounds by disc diffusion method**

Microorganisms	Diameter of zone of inhibition (in mm)												
	SR <sub>4</sub>		SR <sub>5</sub>		SR <sub>6</sub>		SR <sub>7</sub>		SR <sub>8</sub>		SR <sub>9</sub>		Ciprofloxacin
	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/ disc)	(µg/disc)
	25	100	25	100	25	100	25	100	25	100	25	100	100
<i>Staphylococcus aureus</i>	17	21	17	25	12	17.3	12	15	11	15.6	10	16	28
<i>Bacillus subtilis</i>	13	17	11	14	21	27	11	16.4	12.6	17.5	13	16	29
<i>Escherichia coli</i>	12	17	13	17	19	22.3	20	25	21	27	14	17	30
<i>Pseudomonas aeruginosa</i>	15	18	17	22	20	24	17	21.5	21	26	14	17	32

**b) Evaluation of in vitro antifungal activity:**

The synthesized compounds (SR<sub>4</sub> - SR<sub>9</sub>) were tested for anti-fungal activity by disc diffusion method. They were dissolved in DMSO and sterilized by filtering through 0.45 µm millipore filter. Final inoculum of 100 µl suspension containing 10<sup>8</sup> CFU / ml of each fungus was used. Sabouraud’s dextrose agar medium was prepared and sterilized by an autoclave (121° C and 15 lbs for 20 min) and transferred to previously sterilized petridishes (9 cm in diameter).

After solidification, petriplates were inoculated with fungal organisms *Candida albicans* ATCC 24433 and *Trichophyton rubrum* ATCC 2327 in sterile sabouraud’s dextrose agar medium at 45° C in aseptic condition. Sterile Whatmann filter paper discs (previously sterilized in U.V. lamp) were impregnated with synthesized compounds at a concentration of 25, 100 µg/ disc were placed in the organism-impregnated petri plates under sterile condition. The plates were left for 30 min to allow the diffusion of compounds at room temperature. Antibiotic disc of ketaconazole (100 µg/ disc) were used as positive control, while DMSO used as negative control. Then the plates were incubated for 48 h at 37±1° C for antifungal activity.

The zone of inhibition (**Table-3**) was calculated by measuring the minimum dimension of the zone of no microbial growth around each disc.

**Table 3: *In vitro* antifungal activity of synthesized compounds by disc diffusion method**

Microorganisms	Diameter of zone of inhibition (in mm)												
	SR <sub>4</sub> (µg/ disc)		SR <sub>5</sub> (µg/ disc)		SR <sub>6</sub> (µg/ disc)		SR <sub>7</sub> (µg/ disc)		SR <sub>8</sub> (µg/ disc)		SR <sub>9</sub> (µg/ disc)		Ketoconazole (µg/ disc)
	25	100	25	100	25	100	25	100	25	100	25	100	100
<i>Candida albicans</i>	16	21	17	21	14	17	11	14	20	22	23	26	31
<i>Trichophyton rubrum</i>	12	15	14	17.5	16	19.1	13	18	17	20	24	29	30

**RESULTS AND DISCUSSION :**

**1. Experimental Section-**

The study involves the replacement of N-1 hydrogen of novel benzimidazole derivatives with different types of substitutions like sulphanilamide and piperazine to form N-methyl substituted benzimidazole derivatives by mannich reaction. The structure of the synthesized compounds were elucidated by physical and spectral (UV, IR, <sup>1</sup>H NMR and Mass) analysis. The physical and analytical data of synthesized compounds were presented in **Table 1**. The NH band (3164-3385 cm<sup>-1</sup>) and NH proton signal (δ 4.80 – 5.0 ppm) of 2-substituted benzimidazole in IR and <sup>1</sup>H NMR spectrum respectively in the synthesized compounds (SR<sub>1</sub>–SR<sub>3</sub>), confirmed the formation of benzimidazole nucleus.

In SR<sub>1</sub>, <sup>1</sup>H NMR spectrum showed a singlet for 3 protons at δ 2.42 confirmed the substitution of methyl group at C2 of benzimidazole nucleus. In SR<sub>2</sub>, gave quartet peak for 2 protons at δ 2.59 and a triplet peak

for 3 protons at  $\delta$  1.27 indicated the presence of ethyl group at C2 of benzimidazole. In SR<sub>3</sub>, a two triplet peak for 5 protons at  $\delta$  2.55 and  $\delta$  0.96 and a multiplet peak for 2 protons at  $\delta$  1.66 indicated the presence of propyl group at C2 of benzimidazole.

The IR spectrum of each N-mannich bases of SR<sub>4</sub> to SR<sub>6</sub> showed the characteristic IR absorption bands in the region of 3376-3385 cm<sup>-1</sup>, 3263-3289 cm<sup>-1</sup> and 1312-1320 cm<sup>-1</sup> due to the presence of primary amino, secondary amino and SO<sub>2</sub> stretching of sulphonamide moiety. The structural confirmation of each N-mannich bases of SR<sub>4</sub> to SR<sub>6</sub> was further made using <sup>1</sup>H NMR spectra. It showed signals at  $\delta$ , ppm: 6.06 - 6.18 (2H, s, -CH<sub>2</sub> proton), 4.57 - 4.60 (2H, s, SO<sub>2</sub>NH<sub>2</sub> proton) and 5.76 - 5.83 (1H, s, NH of sulphonamide). Thus, confirmed the proposed structures for above N-mannich bases of corresponding 2-substituted benzimidazole derivatives.

The IR spectrum of each N-mannich bases of SR<sub>7</sub> to SR<sub>9</sub> showed the characteristic IR absorption bands in the region of 3385 - 3416 cm<sup>-1</sup> due to the presence of 2° N-H (secondary amino) stretching of piperazine ring. The structural confirmation of each N-mannich bases of SR<sub>7</sub> to SR<sub>9</sub> was further made using <sup>1</sup>H NMR spectra. The spectral data of compounds (SR<sub>1</sub> to SR<sub>9</sub>) were presented in below. It showed signals at  $\delta$ , ppm: 2.37 - 2.93 (8H, m, -CH<sub>2</sub> of piperazine), 5.47 - 5.61 (2H, s, CH<sub>2</sub> proton) and 1.13 - 1.15 (1H, s, NH of piperazine).

Thus, confirmed the proposed structures for above N-mannich bases of corresponding 2-substituted benzimidazole derivatives. The structural confirmation of synthesized compounds of SR<sub>1</sub> to SR<sub>9</sub> was further made using Mass spectra. The molecular ion (M<sup>+</sup>) peaks such as 132.12, 146.21, 160.11, 316.37, 330.40, 344.43, 230.30, 244.33 and 258.36 for SR<sub>1</sub>, SR<sub>2</sub>, SR<sub>3</sub>, SR<sub>4</sub>, SR<sub>5</sub>, SR<sub>6</sub>, SR<sub>7</sub>, SR<sub>8</sub> and SR<sub>9</sub> respectively corresponded with their molecular weights. The predicted chemical structure of title compounds was further supported by the fragmentation peaks.

## 2. Biological Screening –

The compounds were screened for their antibacterial and antifungal activities. The activities reported by means of zone of inhibition in millimeter. All the compounds showed very good antibacterial and antifungal activities at the tested dose level.

### a) Evaluation of *in vitro* antibacterial activity:

The sulphanilamide group containing N-mannich bases were more superior for inhibiting the growth of *Staphylococcus aureus* and *Bacillus subtilis* than piperazine containing N-mannich bases. Among the compounds, SR<sub>4</sub> to SR<sub>6</sub>, the compound SR<sub>5</sub> was more active than the other compounds against the growth of *Staphylococcus aureus*. Likewise, the compound SR<sub>6</sub> was more active than SR<sub>4</sub> and SR<sub>5</sub> to inhibit the growth of *Bacillus subtilis*.

The piperazine group containing N-mannich bases were more superior for inhibiting the growth of *Escherichia coli* and *Pseudomonas aeruginosa* than sulphanilamide group containing N-mannich bases. Among the compounds SR<sub>7</sub> to SR<sub>9</sub>, the compound SR<sub>8</sub> was more active than the other compounds against the growth of *Escherichia coli* and *Pseudomonas aeruginosa*.

Among the tested compounds, piperazine derivatives were more superior to sulphanilamide derivatives against gram negative bacteria. But sulphanilamide derivatives were more active than piperazine derivatives against gram positive bacteria. The *In vitro* antibacterial activity of synthesized compounds is presented in **Table 2**.

**b) Evaluation of *in vitro* antifungal activity:**

The anti-fungal evaluation of compounds (SR<sub>4</sub> to SR<sub>9</sub>), the piperazine group containing N-mannich bases were more superior for inhibiting the growth of *Candida albicans* and *Trichophyton rubrum* than sulphanilamide group containing N-mannich bases. Among the compounds of SR<sub>7</sub> to SR<sub>9</sub>, the compound SR<sub>9</sub> was more active than the other compounds against the growth of *Candida albicans* and *Trichophyton rubrum*. The *In vitro* antifungal activity of synthesized compounds is presented in **Table 3**.

**CONCLUSION :**

The study suggests that the benzimidazole ring is an important pharmacophore in modern drug discovery and the tested derivatives of benzimidazoles have excellent scope for further development as commercial antimicrobial agents in the chemotherapeutic approach in humans. All the synthesized compounds showed very good antibacterial and antifungal activities at the tested dose level. This activity of synthesized compounds can be increased (or) equalized by altering the number of carbon atoms in side chain (or) introducing aromatic ring (or) substituted aromatic ring (or) heterocyclic ring (or) by introducing double bond in side chain in the 2nd position of benzimidazole nucleus.

**REFERENCES :**

1. Donald J. Abraham. Burger's Medicinal Chemistry and Drug Discovery, 6th edn., John Wiley and Sons Inc, London, 2002, 417-425.
2. Suman Sahoo, Trissa Joseph and Halligudi S.B. Mannich reaction in Bronsted acidic ionic liquid: A facile synthesis of  $\alpha$ -amino carbonyl compounds, *Journal of Molecular Catalysis A: Chemical*, 2006, 244, 179–182.
3. Agarwal O.P. Reactions and Reagents, Organic Chemistry, Krishna Prakashan Media (P) Ltd, Meerut, 45th edn., 2008, 804-809.
4. Pandey S.N, Lakshmi V.S and Patel A. Biological activity of mannich bases, *Indian Journal of Pharmaceutical Sciences*, 2003, 65 (3), 213-221.
5. Rita Bannela, Mukesh K. Ahirwar and Shrivastara S.P. Synthesis, characterization and biological activity studies of some N-mannich bases of 1-substituted methyl-2-(substituted phenyl)benzimidazoles, *Asian Journal of Chemistry*, 2011, 23 (4), 1719-1722.
6. Mariappan G, Bhuyan N.R, Pradeep Kumar, Deepak Kumar and Murali K. Synthesis and biological evaluation of mannich bases of benzimidazole derivatives, *Indian Journal of Chemistry*, 2011, 50 (B), 1216-1219.
7. Murugesan Sugumaran and Sathiyamoorthy Sivadevi. Synthesis, spectral analysis and biological activity of mannich bases of 2-substituted benzimidazoles, *Journal of Pharmacy Research*, 2011, 4 (8), 2679-2681.
8. Pankaj Srivastava, Munendra M. Varshney, Dheeraj Kumar and Priyanka Sisodia. Synthesis and evaluation of mannich bases 2-(benzimidazolyl amino methyl) thiazolidin-4-one as antimicrobial agents, *Asian Journal of Chemistry*, 2009, 21 (6), 4273-4279.